When prescription medications become unaffordable, people struggling with addiction often turn to cheaper, far more dangerous street drugs. Prescription drug prices increased by more than 15% from 2022 to 2023, creating a financial barrier that forces many people to seek alternatives in illegal markets. According to the 2025 National Survey on Drug Use and Health, more than 69.8 million Americans reported using illicit drugs or misusing prescription drugs. In 2025 alone, 69,973 people in the US died from drug overdoses, many of them driven to street drugs by cost alone.

How Does the Cost of Addiction Compare Across Different Drugs?

The financial burden of addiction varies dramatically depending on the substance. Illicit-market prices are influenced by supply, demand, geographic location, and drug type, making them difficult to predict or compare. However, understanding these costs reveals why people with limited resources face impossible choices between legal treatment and survival.

Opioid addiction presents one of the most complex pricing landscapes. Prescription opioids like oxycodone (15mg) cost between $1.20 and $1.50 per pill without insurance, while the same drug sells for $15 to $30 per pill on the street. Percocet (10mg/325mg) costs $0.50 to $1.50 per pill with a prescription but $10 to $20 on the street. As tolerance develops, people require higher doses, multiplying their daily costs exponentially.

Illicitly manufactured fentanyl has become the dominant force in the US opioid market. Fentanyl is approximately 50 times more potent than heroin and relatively inexpensive to produce, making it an attractive product for drug traffickers seeking to maximize profit. However, this potency creates catastrophic risks. In 2023, 93% of opioid overdose deaths involved powerful synthetic opioids like fentanyl, and the economic cost of the illicit opioid epidemic reached $2.7 trillion, including $1.11 trillion in losses from premature deaths.

Heroin remains a significant threat despite declining use. A small bag of heroin costs roughly $5 to $20, though prices vary by location and purity. People with severe heroin use disorder have reported using 10 to 15 bags per day, creating daily costs that quickly become unsustainable. The danger intensifies because illicit heroin may contain fentanyl or xylazine without the user's knowledge, making overdose risk unpredictable.

Cocaine addiction ranks among the most expensive stimulant dependencies. The average retail price of cocaine in the United States was approximately $120 per gram in 2021. Consistent users can consume up to 5 grams per day, resulting in annual cocaine addiction costs exceeding $200,000. Crack cocaine, a smokable form that produces a rapid, intense high, costs $60 to $100 per gram and can develop into addiction far more quickly than powder cocaine.

Why Do Prescription Drug Price Increases Lead to Addiction?

The connection between affordability and addiction risk is direct and measurable. When prescription drug prices increase, people who rely on these medications face a stark choice: pay escalating out-of-pocket costs or seek cheaper alternatives. Insurance coverage can reduce costs for legal prescriptions, but those without adequate coverage or insurance face the full burden of rising prices.

Benzodiazepines, commonly prescribed for anxiety and insomnia, illustrate this problem. When used as prescribed, these drugs are safe and effective. However, the high cost of prescription benzodiazepines combined with their addictive potential creates a dangerous scenario. These central nervous system depressants activate powerful reward centers in the brain, causing dopamine release that contributes to feelings of happiness. Over time, the brain adapts and requires larger doses to achieve the same effect, a process called tolerance.

Benzodiazepine dependence differs from addiction but often leads to it. Dependence affects everyone who consistently uses benzodiazepines for multiple days or weeks; the brain adapts and begins to rely on the drugs to function normally. Addiction develops only in some people, but when it does, the disease disrupts judgment, self-control, and motivation, making it nearly impossible to quit without professional help.

What Are the Dangers of Switching to Street Drugs Due to Cost?

The risks of purchasing drugs on the illicit market extend far beyond price. Because illicit drugs are unregulated, there is no reliable way for someone purchasing them to know their exact contents or potency. Fentanyl and other synthetic opioids may be mixed with or sold as other drugs, increasing the risk of accidental exposure and overdose.

• Unpredictable Potency: Street drugs contain unknown amounts of active ingredients, making overdose risk impossible to calculate or prevent, even for experienced users.
• Hidden Adulterants: Illicit opioids frequently contain fentanyl or xylazine without the user's knowledge, dramatically increasing the likelihood of overdose and death.
• No Quality Control: Unlike prescription medications manufactured under FDA oversight, street drugs have zero regulatory standards, meaning each purchase is a gamble with unknown consequences.
• Rapid Addiction Development: Illicit drugs like crack cocaine and fentanyl create addiction far more quickly than their prescription counterparts, trapping users in cycles of dependence within days or weeks.

How Can People Access Treatment When Cost Is a Barrier?

Treatment options exist, but access remains uneven across regions and income levels. Medication-assisted therapy (MAT) combines medications like methadone, buprenorphine, or naltrexone with counseling and behavioral therapies, offering evidence-based recovery pathways for opioid addiction. For benzodiazepine addiction, behavioral therapies prove effective in both inpatient and outpatient settings, including cognitive-behavioral therapy (CBT) and contingency management, which use prize-based systems to reward abstinence.

However, access to inpatient treatment varies dramatically by location. Nova Scotia Health operates only 27 beds across inpatient withdrawal services in three locations, leaving entire regions without access to intensive, round-the-clock care. The Annapolis Valley, where one woman died from alcohol addiction, has no inpatient facility at all. In contrast, neighboring New Brunswick and Prince Edward Island offer extended inpatient programs ranging from 21 to 90 days, demonstrating that more comprehensive services are possible.

Leslie Tilley lost her daughter Barbara to alcohol addiction in February 2026 and believes her death was preventable. Barbara had sought help multiple times at drop-in clinics without success. Leslie, who has herself stayed in inpatient facilities for weeks to achieve sobriety, emphasized the critical difference that extended care makes.

"This is a girl that needed help and wanted help," Leslie said, describing her daughter's desperate attempts to recover.

Leslie Tilley, Mother of Barbara Tilley

Private facilities in Nova Scotia offer both four- and six-week inpatient programs with two years of follow-up services, but these programs cost thousands of dollars, placing them out of reach for most people. Crosbie House Recovery and Addiction Centre reports that three out of four people who complete their inpatient program remain abstinent one year after leaving.

"In an inpatient program, you're allowing the person to solely focus on what their needs are. You're taking them out of the triggers and the stressors and you're getting them out of active addiction," explained Adam Lewis, program manager at Crosbie House.

Adam Lewis, Program Manager at Crosbie House Recovery and Addiction Centre

The gap between what works and what is available reveals a systemic failure. While Nova Scotia Health operates outpatient recovery support centers and opioid recovery clinics, these services cannot replace the intensive, immersive care that many people with severe addiction require. The cost barrier that drives people to street drugs is compounded by the cost barrier that prevents access to effective treatment, creating a cycle of desperation and death.

As prescription drug prices continue to rise and addiction rates remain high, the question facing policymakers is clear: invest in accessible, evidence-based treatment now, or pay the far higher cost of overdose deaths, lost productivity, and shattered families later. The $2.7 trillion economic cost of the illicit opioid epidemic alone suggests that expanding treatment access would be a sound investment in both human lives and public resources.